| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | J A Rey | |
| C A Luque | |||
| P2860 | cites work | A comparison of sibutramine and dexfenfluramine in the treatment of obesity | Q74830575 |
| Valvular heart disease associated with fenfluramine-phentermine | Q28247282 | ||
| Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. | Q35026535 | ||
| Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity | Q35329220 | ||
| Appetite suppressants. A review | Q35329355 | ||
| Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence | Q38473880 | ||
| Medical hazards of obesity | Q40841355 | ||
| Dexfenfluramine. An updated review of its therapeutic use in the management of obesity | Q41445495 | ||
| A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents | Q41894548 | ||
| The effects of BTS 54,505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the rat dorsolateral geniculate nucleus in vivo | Q41897251 | ||
| Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers | Q41938591 | ||
| Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat | Q42057930 | ||
| Characterization of P1-purinoceptors on rat isolated duodenum longitudinal muscle and muscularis mucosae | Q42705852 | ||
| Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants | Q42717226 | ||
| A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine | Q44773878 | ||
| The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride | Q44971989 | ||
| Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine | Q47265863 | ||
| Sibutramine produces dose-related weight loss | Q47268542 | ||
| Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines | Q47287928 | ||
| Effects of sibutramine on resting metabolic rate and weight loss in overweight women | Q47291749 | ||
| Sibutramine in weight control: a dose-ranging, efficacy study | Q47425497 | ||
| The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation | Q48163276 | ||
| [3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments | Q48235129 | ||
| A comparison of various antidepressant drugs demonstrates rapid desensitisation of alpha 2-adrenoceptors exclusively by sibutramine hydrochloride | Q48594070 | ||
| Sibutramine pharmacokinetics in young and elderly healthy subjects. | Q53936931 | ||
| Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults | Q63258542 | ||
| Overweight and obesity in the United States: prevalence and trends, 1960-1994 | Q64133342 | ||
| Effects of antidepressant drugs and electroconvulsive shock on pre- and postsynaptic α2-adrenoceptor function in the brain: rapid down-regulation by sibutramine hydrochloride | Q67916046 | ||
| Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl | Q68732527 | ||
| Antidepressant treatments, including sibutramine hydrochloride and electroconvulsive shock, decrease beta 1- but not beta 2-adrenoceptors in rat cortex | Q69355041 | ||
| [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments | Q71201871 | ||
| A double-blind randomized placebo-controlled trial of sibutramine | Q71329417 | ||
| D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function | Q71479809 | ||
| Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity | Q71899836 | ||
| Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine | Q73626953 | ||
| Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study | Q74240207 | ||
| Sibutramine reduces food intake in non-dieting women with obesity | Q74397262 | ||
| The cost of obesity: the US perspective | Q74823666 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| obesity | Q12174 | ||
| (RS)-sibutramine | Q424151 | ||
| norepinephrine | Q186242 | ||
| P304 | page(s) | 968-78 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity | |
| P478 | volume | 33 |
| Q41980535 | 5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials |
| Q37995983 | A review of unmet needs in obesity management |
| Q36007869 | Advances in diabetes for the millennium: nutritional therapy of type 2 diabetes |
| Q42825533 | Anti-Obesity Effects of the Mixture of Eriobotrya japonica and Nelumbo nucifera in Adipocytes and High-Fat Diet-Induced Obese Mice. |
| Q42321603 | Anti-obesity effects of Boussingaulti gracilis Miers var. pseudobaselloides Bailey via activation of AMP-activated protein kinase in 3T3-L1 cells |
| Q33841823 | Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism. |
| Q36995285 | Antiadipogenic Effects of Aster glehni Extract: In Vivo and In Vitro Effects. |
| Q29308187 | Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects |
| Q27902304 | ChemDIS: a chemical–disease inference system based on chemical–protein interactions |
| Q34983224 | Chinese slimming capsules containing sibutramine sold over the Internet: a case series |
| Q53069361 | Combination of Garcinia cambogia Extract and Pear Pomace Extract Additively Suppresses Adipogenesis and Enhances Lipolysis in 3T3-L1 Cells. |
| Q45097301 | Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. |
| Q43236004 | Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women |
| Q35992004 | Contemporary approaches into obesity: drugs and genes |
| Q46316802 | Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation |
| Q43944301 | Effects of sibutramine in non-dieting obese women |
| Q46422665 | Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. |
| Q43882702 | Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial |
| Q46336288 | Electrophysiological safety of sibutramine HCl. |
| Q33805817 | Extracts from "Clinical Evidence". Obesity. |
| Q35060413 | HOX-7 suppresses body weight gain and adipogenesis-related gene expression in high-fat-diet-induced obese mice |
| Q44525141 | Health risks, past usage, and intention to use weight loss products in normal weight women with high and low body dysphoria |
| Q37733914 | Identification and determination of synthetic pharmaceuticals as adulterants in eight common herbal weight loss supplements. |
| Q38827616 | Inhibitory effects of Aster spathulifolius extract on adipogenesis and lipid accumulation in 3T3-L1 preadipocytes |
| Q44482870 | Interaction between sibutramine and cyclosporine |
| Q37173554 | Interaction of Veratrum nigrum with Panax ginseng against Obesity: A Sang-ban Relationship |
| Q38289411 | Korean Chungtaejeon tea extract attenuates body weight gain in C57BL/6J-Lep ob/ob mice and regulates adipogenesis and lipolysis in 3T3-L1 adipocytes. |
| Q24247723 | Long-term pharmacotherapy for obesity and overweight |
| Q35029802 | Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options |
| Q34788366 | Modafinil decreases food intake in humans subjected to simulated shift work |
| Q28066691 | Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases |
| Q48706402 | Narcolepsy and obesity: remission of severe cataplexy with sibutramine |
| Q38998472 | New actions of an old friend: perivascular adipose tissue's adrenergic mechanisms. |
| Q37061997 | Obesity: a review of pathogenesis and management strategies |
| Q34014388 | Obesity: an epidemic in need of therapeutics |
| Q24792455 | Obesity: an overview on its current perspectives and treatment options |
| Q34182135 | Orlistat in the treatment of obesity |
| Q34191297 | Orlistat--a novel weight loss therapy |
| Q33996725 | Pharmacological treatment of obesity |
| Q22251113 | Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA) |
| Q37585306 | Polycystic ovary syndrome, obesity and reproductive implications |
| Q53687735 | Potential Hypoglycaemic and Antiobesity Effects of Senna italica Leaf Acetone Extract. |
| Q36936358 | Present and future therapeutic strategies in non-alcoholic fatty liver disease |
| Q42850075 | Psychosis associated with usage of herbal slimming products adulterated with sibutramine: a case series |
| Q45908028 | Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist. |
| Q24244078 | Rimonabant for overweight or obesity |
| Q45935486 | Serotonin syndrome following sibutramine poisoning in a child, with sequential quantification of sibutramine and its primary and secondary amine metabolites in plasma. |
| Q43011934 | Sibutramine effects on the reproductive performance of pregnant overweight and non-overweight rats |
| Q43882700 | Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors |
| Q34585304 | Sibutramine-associated adverse effects: a practical guide for its safe use. |
| Q58068053 | The Effect of Sibutramine, a Serotonin-Norepinephrine Reuptake Inhibitor, on Platelets and Fibrin Networks of Male Sprague-Dawley Rats: A Descriptive Study |
| Q34128195 | The discovery and status of sibutramine as an anti-obesity drug |
| Q46419827 | The stereoselective biotransformation of the anti-obesity drug sibutramine in rat liver microsomes and in primary cultures of rat hepatocytes |
| Q35102481 | Understanding the new and evolving profile of adverse drug effects in schizophrenia |
| Q35563443 | Use of sibutramine to treat obesity |
| Q36814522 | Veratri Nigri Rhizoma et Radix (Veratrum nigrum L.) and Its Constituent Jervine Prevent Adipogenesis via Activation of the LKB1-AMPKα-ACC Axis In Vivo and In Vitro |
| Q75344159 | [Overweight and obesity in adults: recommendations and treatment algorithms] |
Search more.